Undoubtedly, the presumed association must be confirmed in a larger CKD/ESRD population, especially if genetic screening is to be used as a tool for predicting the risk of CKD progression and whether the pharmacological NLRP3 pathway inhibition will be included in the therapeutic armamentarium against renal diseases. Here, NLRP3 is linked to kidney disorder.